Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ) has shared an announcement.
Qyuns Therapeutics has scheduled a board meeting for March 27, 2026 to review and approve the group’s annual results for the financial year ended December 31, 2025 and to authorize their publication. The board will also consider whether to recommend a final dividend and may address other corporate matters, signaling upcoming disclosures that could influence shareholder expectations and the company’s capital management outlook.
The announcement also confirms the current composition of the board, led by chairman and executive director Qiu Jiwan and supported by a mix of executive, non-executive and independent non-executive directors. This governance structure underscores the company’s adherence to Hong Kong listing requirements and provides continuity as Qyuns approaches a key financial reporting and potential dividend decision point.
The most recent analyst rating on (HK:2509) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Qyuns Therapeutics Co., Ltd. Class H stock, see the HK:2509 Stock Forecast page.
More about Qyuns Therapeutics Co., Ltd. Class H
Qyuns Therapeutics Co., Ltd. is a biopharmaceutical company based in the People’s Republic of China and listed in Hong Kong under stock code 2509. The group focuses on developing and commercializing therapeutic products, with operations overseen by a board comprising executive, non-executive and independent non-executive directors.
Average Trading Volume: 257,245
Technical Sentiment Signal: Sell
Current Market Cap: HK$4.11B
See more data about 2509 stock on TipRanks’ Stock Analysis page.